ClinicalTrials.Veeva

Menu

Study Evaluating Bifeprunox in Bipolar Depression

Wyeth logo

Wyeth

Status and phase

Completed
Phase 3

Conditions

Depression Bipolar

Treatments

Drug: Bifeprunox

Study type

Interventional

Funder types

Industry

Identifiers

NCT00245973
3168A2-307

Details and patient eligibility

About

The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of Bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women 18 to 65 years of age, inclusive.
  • Diagnosis of Bipolar Disorder and must be experiencing a depressive episode.

Exclusion criteria

  • This is a follow on study to protocol 3168A2-304. Only subjects who have participated in the previous study are eligible.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

40

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems